Medical cannabis authorization and the risk of cardiovascular events : a longitudinal cohort study Arsene Zongo, Cerina Lee, Jason R. B. Dyck, Jihane El‑Mourad, Elaine Hyshka, John G. Hanlon and Dean T. Eurich BMC Cardiovascular Disorders, 2021, 21, 426 doi : 10.1186/s12872-021-02229-6 Abstract Background : Cannabis is increasingly used for therapeutic purpose. However, its safety profile is not well known. This study assessed the risk of cardiovascular-related emergency department (ED) visit and hospitalization in adult patients authorized to use medical cannabis in Ontario, Canada from 2014 to 2017. Methods : This is a longitudinal cohort study of patients who received medical cannabis authorization and followedup in [...]
Lire la suiteSynthetic cannabinoids and potential cardiac arrhythmia risk : an important message for drug users Jules C. Hancox, Nicola J. Kalk and Graeme Henderson Therapeutic Advances in Drug Safety, 2020, 11, 1-4. Doi : 10.1177/2042098620913416 Δ9-Tetrahydrocannabinol, the psychoactive ingredient in cannabis, and synthetic cannabinoid receptor agonists (SCRAs) activate the CB1 receptor to produce their profound behavioural effects and are widely used as recreational drugs. There is growing evidence that SCRAs, commonly known by the street name Spice or K2 (though there are many others, see: http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cannabinoids) can produce detrimental cardiovascular effects.(1) Commonly observed cardiotoxic effects of SCRAs include tachycardia, chest pain and hypertension.(1) However, bradycardia and [...]
Lire la suite5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats Leonardo B.M. Resstel, Rodrigo F. Tavares, Sabrina F.S. Lisboa, Sâmia R.L. Joca, Fernando M.A. Corrêa and Francisco S. Guimarães British Journal of Pharmacology, 2009, 156, 181–188; doi : 10.1111/j.1476-5381.2008.00046.x Background and purpose : Cannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa which induces anxiolytic- and antipsychotic-like effects in rodents. These effects could be mediated by facilitation of the endocannabinoid system or by the activation of 5-HT1A receptors. As either of these mechanisms could promote adaptation to inescapable stress, the aim of the present work [...]
Lire la suiteMarijuana use and coronary artery disease in young adults Jeremy R. Burt, Ali M. Agha, Basel Yacoub, Aryan Zahergivar, Julie Pepe PLoS ONE, 2020, 15, (1), e0228326, 1-8. Doi : 10.1371/journal.pone.0228326 Abstract Background Marijuana is the most popular drug of abuse in the United States. The association between its use and coronary artery disease has not yet been fully elucidated. This study aims to determine the frequency of coronary artery disease among young to middle aged adults presenting with chest pain who currently use marijuana as compared to nonusers. Methods In this retrospective study, 1,420 patients with chest pain or angina equivalent were studied. Only men between 18 [...]
Lire la suiteBibliographie Cannabis et Troubles cardio-vasculaires Dr Christian SUEUR, GRECC, 2e édition, janvier 2020. Actuellement, les méta-analyses ne montrent pas d'augmentation significative des pathologies cardiovasculaire chez les consommateurs de cannabis. (cf en particulier la méta-analyse de Divya RAVI et coll., Annals of Internal Medicine, 2018). Quoiqu'il en soit, l'existence de facteurs de risques liés à la consommation de cannabis fumé est semble-t-il incontestable; de même, les risques sont vraisemblablement augmentés chez les sujets prédisposés, présentant des pathologies cariaques, vasculaires, des troubles de l'excitabilité cardiaque ou de la tension artérielle. La plupart des "Case Report" consistent en des accidents par sténose vasculaire, cérébrale ou cardiaque, [...]
Lire la suiteMedical Consequences of Cannabis Use Jag H. Khalsa, MS, PhD and Ruben Baler, PhD National Institute on Drug Abuse, National Institutes of Health, Bethesda, Janvier 2019 Disclaimer: The opinions in this paper are of authors and do not reflect the position of the National Institute on Drug Abuse, National Institutes of Health. Abstract Consumed by an estimated 2.5% of the world’s population, cannabis is the most popular illicit drug. Depending on age of onset, frequency, duration, and other variables, cannabis use can be associated with a broad spectrum of medical consequences, the range of which mirrors the physiological ubiquity and versatility of the endocannabinoid [...]
Lire la suite